<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01307306</url>
  </required_header>
  <id_info>
    <org_study_id>ins_met_jeschke</org_study_id>
    <nct_id>NCT01307306</nct_id>
  </id_info>
  <brief_title>Glucose Control in Severely Burned Patients</brief_title>
  <official_title>Glucose Control in Severely Burned Patients: Mechanisms and Therapeutic Potential</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The central aim of this application is to determine whether improved outcomes with tight
      euglycemic control are due to insulin-specific responses. The investigators hypothesize that
      improving insulin resistance will lead to decreased inflammatory and hypermetabolic
      responses, as well as restored glucose metabolism, and so result in improved clinical outcome
      of severely burned patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Perform oral glucose tolerance test</measure>
    <time_frame>at 1-2 months post-admission, up to 6 months</time_frame>
    <description>Standard fasting oral glucose tolerance test with an intake of 75 g of glucose. Subsequent measurements (in mg/dl) of glucose in blood, insulin and c-peptide will be conducted over 2 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perform oral glucose tolerance test</measure>
    <time_frame>assessed at discharge (1-4 months post admission depending on the severity of injury)</time_frame>
    <description>Standard fasting oral glucose tolerance test with an intake of 75 g of glucose. Subsequent measurements (in mg/dl) of glucose in blood, insulin and c-peptide will be conducted over 2 hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure concentrations of serum cytokines</measure>
    <time_frame>weekly until discharge (1-4 months post admission depending on severity of injury)</time_frame>
    <description>Inflammatory response will be assessed by measuring the concentrations (in pg/ml)of a panel of serum cytokines (IL-1, IFN, TNF etc.) using the Bio-Plex 17-Plex Suspension assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Record the episodes of sepsis</measure>
    <time_frame>daily until discharge (1-4 months post admission depending on severity of injury)</time_frame>
    <description>Patients will be assessed daily for episodes of sepsis. The total number of episodes over the course of hospital stay will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Record the episodes of Pneumonia</measure>
    <time_frame>daily until discharge (1-4 months post admission depending on severity of injury)</time_frame>
    <description>Pneumonia is defined by new progressive and persistent infiltrate, consolidation or cavitations, inhalation injury based on chest X-ray. We will also follow the guidelines provided by the American Burn Association on the definition of Pneumonia in burn patients. Change in sputum (purulent or increased) will also be recorded.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Burns</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Humulin R</intervention_name>
    <description>Humulin R (U-100) will be given i.v. The dose given will be adjusted in order to achieve a blood glucose level of 130-140 mg/dl.</description>
    <arm_group_label>Insulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin 850 mg q. 8 hours will be given to decrease blood glucose to 130-140 mg/dl.</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  between 18 and 90 years of age

          -  &gt;20% TBSA

          -  Admitted to the burn unit within 120 hours following burn

          -  At least 1 surgical intervention necessary

        Exclusion Criteria:

          -  death upon admission

          -  decision not to treat due to burn injury severity

          -  presence of anoxic brain injury that is not expected to result in complete recovery

          -  known history of AIDS, ARC, HIV, Hepatitis B-E

          -  history of cancer within 5 years of malignancy currently under treatment

          -  inability to obtain informed consent

          -  previous or existing renal dysfunction, liver disease, or hepatic dysfunction

          -  pre-existing type I diabetes mellitus

          -  pregnancy

          -  allergy to metformin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc G Jeschke, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marc G Jeschke, MD PhD</last_name>
    <phone>416-480-6703</phone>
    <email>marc.jeschke@sunnybrook.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marjorie A Burnett, HonsBSc</last_name>
    <phone>416-480-6100</phone>
    <phone_ext>88021</phone_ext>
    <email>marjorie.burnett@sunnybrook.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ross Tilley Burn Centre, Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc G Jeschke, MD PhD</last_name>
      <phone>416-480-6703</phone>
      <email>marc.jeschke@sunnybrook.ca</email>
    </contact>
    <contact_backup>
      <last_name>Marjorie Burnett, HonsBSc</last_name>
      <phone>416-480-6100</phone>
      <phone_ext>88021</phone_ext>
      <email>marjorie.burnett@sunnybrook.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Cartotto, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shahriar Shahrokhi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alison Cheung, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2011</study_first_submitted>
  <study_first_submitted_qc>February 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2011</study_first_posted>
  <last_update_submitted>October 17, 2016</last_update_submitted>
  <last_update_submitted_qc>October 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sunnybrook Health Sciences Centre</investigator_affiliation>
    <investigator_full_name>Dr. Marc Jeschke</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Thermal injury</keyword>
  <keyword>Chemical Burn</keyword>
  <keyword>Flame Burn</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

